Regardless of the potential of anti-inflammatory properties of GLP-1 receptor agonists [61] and SGLT2 inhibitors [62] to ameliorate hearing impairment [7,8,9,63], this physiopathology might not be able to reverse the potential ototoxicity effect mentioned above. The gene discussed is GLP1R; the disease is hearing loss disorder.